SYSTEMATIC REVIEW article

Front. Physiol., 17 October 2017

Sec. Exercise Physiology

Volume 8 - 2017 | https://doi.org/10.3389/fphys.2017.00779

Acute and Chronic Effects of Endurance Running on Inflammatory Markers: A Systematic Review

  • 1. Physical Education, Catholic University of Brasilia, Brasília, Brazil

  • 2. Medical Sciences, University of Brasilia, Brasília, Brazil

  • 3. Sport and Exercise Science, College of Healthcare Sciences, James Cook University, Townsville, QLD, Australia

Article metrics

View details

45

Citations

18,3k

Views

3k

Downloads

Abstract

In order to understand the effect of endurance running on inflammation, it is necessary to quantify the extent to which acute and chronic running affects inflammatory mediators. The aim of this study was to summarize the literature on the effects of endurance running on inflammation mediators. Electronic searches were conducted on PubMED and Science Direct with no limits of date and language of publication. Randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs) investigating the acute and chronic effects of running on inflammation markers in runners were reviewed by two researchers for eligibility. The modified Downs and Black checklist for the assesssments of the methodological quality of studies was subsequently used. Fifty-one studies were finally included. There were no studies with elite athletes. Only two studies were chronic interventions. Results revealed that acute and chronic endurance running may affect anti- and pro-inflammatory markers but methodological differences between studies do not allow comparisons or generalization of the results. The information provided in this systematic review would help practitioners for better designing further studies while providing reference values for a better understanding of inflammatory responses after different running events. Further longitudinal studies are needed to identify the influence of training load parameters on inflammatory markers in runners of different levels and training background.

Introduction

Running is an important natural ability of our species that has contributed to our survival and body adaptations (Bramble and Lieberman, 2004). In the Paleolithic Era, survival was dependent on hunting and gathering, and therefore it has been suggested that the ancient physical activity pattern included mostly prolonged, low-intensity physical activities, including endurance running, interspersed with high-intensity bursts of activity (O'Keefe et al., 2010; Boullosa et al., 2013). Nowadays, endurance running is probably the most popular sport worlwide and it is practiced for recreational, health and competitive purposes (Chiampas and Goyal, 2015).

There is a close link between endurance running and the activity of the immune system. The importance of this relationship has led to important investigations over the last decades. Previously, Peters and Bateman (1983) identified an increased prevalence of upper respiratory tract infection (URTI) in 150 runners following a 56.0 km ultramarathon. Subsequently, specialized literature has suggested that even highly trained individuals, when subjected to frequent strenuous exercise, could develop a pro-inflammatory condition that favors the onset of a number of health problems, including damage to myocardial cells and connective tissues, overload of the atria and right ventricle, coronary artery disease (CAD), and coronary artery calcification among others (Peters and Bateman, 1983; Febbraio and Pedersen, 2005; Petersen and Pedersen, 2005; Zaldivar et al., 2006; Mohlenkamp et al., 2007; Hubble et al., 2009; Nieman, 2009; Meeusen et al., 2013; O'Keefe and Lavie, 2013; Taylor et al., 2014). However, little is known about whether the development of these chronic pathologies is the result of an excess of training volume, intensity, or both, associated with an insufficient recovery, which often promotes an increased susceptibility to infections and subsequent reduction in performance (Smith, 2004; Zaldivar et al., 2006; Hubble et al., 2009). Furthermore, systematic and non-systematic inflammation after running might be related with functional overreaching (Steinacker et al., 2004). In contrast, it has been suggested that periodised training with adequate recovery may be associated with positive adaptations including an adequate balance between pro-inflammatory and anti-inflammatory responses (Febbraio and Pedersen, 2005; Petersen and Pedersen, 2005; Zaldivar et al., 2006).

A growing body of evidence highlights the importance of studying inflammation promoted by endurance running as a factor which is linked to the physiopathology of a number of cardiovascular diseases (Mohlenkamp et al., 2007). It has also been suggested a link between myocardial damage and small thrombotic or even atherosclerotic emboli following a marathon, or after a quick session of exercise, accompanied by a transient monocytosis (about 2 h) (Walsh et al., 2011). The tissue factor is known as the key initiator of coagulation, and is highly dependent on vascular injury and mediators of inflammation such as tumor necrosis factor alpha (TNF-α), which has been reported to increase during and predominantly after marathon running (O'Brien, 2012; Gill et al., 2015b).

Contrary to other endurance sports, eccentric muscle contractions play a key role in running exercises, leading up to the occurrence of different levels of damage in muscle, connective and bone tissues (Suzuki et al., 2003; Jarvinen et al., 2013). The repair of these tissues involves the presence of inflammatory cells into the damaged site, which stimulates the release of pro-inflammatory cytokines such as TNF-α and interleukin-1 beta (IL-1β), thus triggering inflammation (Nieman et al., 1989, 1990). However, little is known about the impact of this chronic cycle tissue damage and repair in runners.

On the other hand, it is also important to emphasize that signaling promoted by repeated muscle contractions as in running, stimulates the production of anti-inflammatory mediators by myocytes, especially interleukin-6 (IL-6), which acts as an inhibitor of pro-inflammatory cytokines such as TNF-α by stimulating the production of its soluble receptor antagonists (Pedersen, 2013). In addition, IL-6 also stimulates the production of interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1ra), generating an anti-inflammatory environment which may counterbalance the pro-inflammatory responses associated to repetitive eccentric actions (Pedersen and Febbraio, 2012).

Despite the growing body of evidence regarding the effects of endurance running on inflammation, the link between transient acute responses and chronic adaptations needs to be addressed (Gleeson, 2007). This information would be important to shed light on the possible role of the inflammatory milieu in the pathophysiology of a number of diseases, especially the cardiovascular ones. Thus, the aim of this systematic review was to investigate the effects of different doses (i.e., training and competitive loads) of endurance running on the acute and chronic inflammatory responses, and the immune effects of this practice on runners of different levels and training backgrounds.

Methods

Search strategy

A systematic review was conducted and the recommendations from the Preferred Reporting Itens for Systematic Review and Meta-Analyses (PRISMA) were considered (Liberati et al., 2009). The search strategies were reported to ensure the integrity of the results and allow the updating using the same methods to bring emerging evidence into the review. The Boolean and proximity operators were used and the search strategy was correctly adapted for each database used (Table 1) (Sampson et al., 2008, 2009). Studies were identified by searching the following electronic databases: PubMED/MEDLINE (via National Library of Medicine) (2000–2017) and Science Direct (Elsevier) (2000–2017). The last search was conducted in February 2017.

Table 1

DatabaseSearch strategyHitsNo. (%) of trials finally selected
PubMED/MEDLINE—via national library of medicine1. Inflammation AND aerobic exercise AND runners;12850
2. Cytokines AND runn* AND (marathon runners or novice runners);64
Total: 192
Science Direct (Elsevier)1. “marathon runners” OR “novice runners” AND “cytokines”;944
Total: 94
Other sources (reference lists of the papers that fulfilled the inclusion criteria were analyzed for the identification of additional studies)Total: 196

Search strategies.

*

Truncation or wildcard.

Once the abstracts were reviewed, the complete versions of the papers that met the criteria were obtained. In addition, the reference lists of the papers that fulfilled the inclusion criteria were analyzed for identification of additional studies. The exclusion of studies with irrelevant content and duplicates was carried out after the title, abstract and full-text were read.

Definition of terms

An “athlete” was defined according to the Medical Subject Headings (MeSH) and was considered to be an individual who has developed skills, physical fitness and strength, or who has participated in sports running (MeSH, 2015). We have considered the definition proposed by Stirling and Kerr (2006) that defines a “recreational athlete” as being an individual who plays on a sports team at an amateur level, works out 1–4 times a week, does not train and compete nationally or internationally, and does not train for the same activity for more than 8 h per week. Novice runners were those individuals who had not been running on a regular basis in the previous 12 months (10 km total in all training sessions in the previous 12 months), and recreational runners were considered as individuals running a mean of 24.94 km/week (Videbaek et al., 2015).

The following thesaurus terms registered in the database from MeSH were also used: “running,” “aerobic exercise,” “inflammation,” and “cytokines.” These terms were associated with the free terms “recreational runners,” “novice runners,” “marathon runners,” and “ultramarathon.”

Inclusion and exclusion criteria

The inclusion criteria were as follows: randomized controlled trials (RCTs) and non-randomized controlled trials (NRCTs); studies investigating the acute and chronic effects of running on markers of inflammation in marathon runners, recreational runners and novice runners; the terms runners, marathon runners, recreational runners and novice runners should be cited in the paper; only healthy participants; only full-text article citations with no restriction on languages; with individuals aged over 19 as the World Health Organisation (WHO) defines adolescence as the period in human growth and development that occurs between childhood and adulthood, from ages 10–19 (WHO, 2015)1. Meeting abstracts, unpublished data, observational studies, review articles, studies using walking and jogging as independent variables, and studies on the effects of any kind of supplements on running, diet restrictions, use of devices (e.g., equipment, compression garments), comparisons between running and other sports, and effects of environmental conditions (ex. dry and hot) were excluded.

Outcome measures

The outcome measures assessed for acute and chronic effects of marathon and recreational running were interleukin (IL): IL-6, IL-10, IL-8, IL-1ra, IL-1β, IL-2 and IL-12, TNF-α, C reactive-protein (CRP), interferon-gamma (IFN-γ), soluble receptors, and transformation growth factor-beta (TGF-β). These mediators were chosen after an initial analysis and review of the literature. They were identified as the main outcomes in studies published with marathon runners, recreational runners and novice runners (Nieman et al., 2005; Santos et al., 2007; Scott et al., 2011; Abbasi et al., 2013; Jee et al., 2013; Shin and Lee, 2013).

Quality assessment

The quality and assessment of all eligible articles was evaluated using a modified version of the Downs and Black checklist (Downs and Black, 1998). Disagreements between authors were discussed and subsequently solved. This modified version consists of 27 objective questions (Downs and Black, 1998).

Results

Research strategy

Results of the research strategy are presented in Figure 1. Initially, 60 studies were selected, with 51 studies being finally included according to the inclusion/exclusion criteria. Nine studies were excluded as follows: one study was excluded due to the use of heat stress, three because the subjects were adolescents, one following the reading of the full paper, two because of comparison with other sporting activities, and one because of medication use; in addition, one paper was not available in full-text version (Saravia et al., 2010). A total of 49 studies verified the acute effect of running on inflammation and two studies focused on the chronic effects.

Figure 1

Figure 1

Summary of search results.

Methodological quality assessment

Quality assessment of the studies according to the modified Downs and Black scale is summarized in Table 2. One important finding was that characteristics of the patients' included were not cleary described in 32 studies. Important adverse events and description of patients' characteristics lost to follow-up was not reported in 34 and 32 studies, respectively. None of the studies were randomized controlled trials and power was provided in 4 studies (Table 2).

Table 2

StudyQuestions
ReportingExternal validityInternal validity (bias)Internal validity—confounding (selection bias)Power
123456789101112131415161718192021222324252627
Grabs et al., 201511111110010*0*10*0*0110*11100000
Fallon et al., 200111111111010*0*10*0*0110*10100000
Kim et al., 201511111110000*0*10*0*0110*10000001
Gill et al., 2015b11011110010*0*10*0*0110*11100000
Mattusch et al., 200011011110000*0*10*0*0110*10100000
Neidhart et al., 200011011110010*0*10*0*0110*10000000
Vaisberg et al., 201311011110010*0*10*0*0110*11000000
Niess et al., 200011011110000*0*10*0*0110*10000000
Kasprowicz et al., 201311001110000*0*10*0*0110*10000000
Saugy et al., 201311011110110*0*10*0*0110*10100010
Jee et al., 201311111110100*0*10*0*0110*10000011
Karstoft et al., 201311011111100*0*10*0*0110*10000010
Wilhelm et al., 201411111111110*0*10*0*0110*11100010
Reihmane et al., 201311011111000*0*10*0*0110*10000000
Millet et al., 201111011110110*0*10*0*0110*10000000
Auersperger et al., 201211111111110*0*10*0*0110*10000110
Bernecker et al., 201311111111110*0*10*0*0110*11100110
Chimenti et al., 200911011111000*0*10*0*0110*11100000
Papassotiriou et al., 200811011110000*0*10*0*0110*11100000
Kim et al., 200711011110010*0*10*0*0110*11000000
Peters et al., 200411111111000*0*10*0*0110*11100000
Suzuki et al., 200311011110010*0*10*0*0110*11100000
Bachi et al., 201511011110010*0*10*0*0110*11100000
Kłapcinska et al., 201311011111010*0*10*0*0110*11000000
Rehm et al., 201311111110110*0*10*0*0110*11100010
Fehrenbach et al., 200011011111100*0*10*0*0110*10000010
Schobersberger et al., 200011011110100*0*10*0*0110*11000010
Suzuki et al., 200011111110100*0*10*0*0110*11100010
Vaisberg et al., 201211011110010*0*10*0*0110*10000000
Tomaszewski et al., 200311111110010*0*10*0*0110*11100100
Bonsignore et al., 200211011110010*0*10*0*0110*11100000
Nickel et al., 201211111110000*0*10*0*0110*10000000
Waśkiewicz et al., 201211011110000*0*10*0*0110*10000000
Chimenti et al., 201011011110000*0*10*0*0110*10000000
Ng et al., 200811011111100*0*10*0*0110*11000010
Siegel et al., 200711010110010*0*10*0*0110*11100000
Shin and Lee, 201312111111110*0*10*0*0110*11000010
Jee and Jin, 201211111110100*0*10*0*0110*11000010
Santos et al., 201311011110010*0*10*0*0110*11100000
Hewing et al., 201511111111010*0*10*0*0110*11100100
Nieman et al., 200311111111110*0*10*0*0110*11000010
Uchakin et al., 200311011110010*0*10*0*0110*11100001
Mrakic-Sposta et al., 201511011110100*0*10*0*0010*11000011
Stuempfle et al., 201611111111110*0*10*0*0110*11100010
Nieman et al., 201611011110010*0*10*0*0110*11000000
Arakawa et al., 201611011110000*0*10*0*0110*11000000
Mohamed et al., 201611011110000*0*10*0*0110*11000000
Cairns and Hew-Butler, 201511111111110*0*10*0*0110*11000010
Gill et al., 2015a11010111010*0*10*0*0110*11100000
Krzeminski et al., 201611011110000*0*10*0*0110*10000000
Nielsen et al., 201611110110010*0*10*0*0110*11000000

Methodological quality assessment scores of the included studies.

1 = yes and 0 = no for questions 1, 2, 3, 4, 6, 7, 8, 9, and 10.

For question 5: 2 = yes, 1 = partially, and 0 = no.

For other questions 1 = yes, 0 = no, and 0* = unable to determine.

Characteristics of the studies and summary of outcome measures

An overview of the studies' characteristics is provided in Table 3 with sample size, age, sex, and exercise protocols. A summary of outcome measures in selected studies is presented on Table 4.

Table 3

CitationAge (years)Exercise group (N) sexTotal subjects (N) male/femaleControl group (N) sexLevel of runnersMethod (distance)Intervention (effects)
AcuteChronic
Grabs et al., 201545.0 ± 8.02020 (♂)ATLMarathon
Fallon et al., 200147.0 ± 7.088 (7♂-1♀)ATLUltra-Marathon: 6 days
Kim et al., 201550.8 ± 8.24040 (♂)LNRMarathon
Gill et al., 2015b41.0 ± 8.0 49.0 ± 4.019 (13♂-6♀)31 (18♂-13♀)12 (5♂-7♀)LNRUltra-marathon: 230 km Five stage (37, 48, 38, 69, 39 km)
Mattusch et al., 2000EG: 25–40 CG: 31–521425 (♂)11RECTraining
Neidhart et al., 2000EG: 25–34 CG: 24–35824 sex (NR)16RECMarathon
Vaisberg et al., 201341.4 ± 9.4Asymptomatic: 15 Symptomatic: 722 (♂)ATLMarathon
Niess et al., 2000EG: 32.3 ± 3.3 CG: 25.0 ± 2.2 Marathon Group: 1018 (♂)8NOVHalf-marathon and treadmill
Kasprowicz et al., 201344.5 ± 13.566 (♂)ATLUltra-marathon: 100 km
Saugy et al., 201345.4 ± 10.3 CG: 29.3 ± 8.12533 (♂)8ATLUltra-marathon: 330 km (Mountain)
Jee et al., 2013EG: 49.75 ± 5.65 CG: 46.75 ± 5.44816 (♂)8ATLUltra-marathon: 308 km
Karstoft et al., 201344 ± 287 (♂) 1 (♀)ATLMarathon
Wilhelm et al., 201434.9 ± 4.21111 (♂)ATLMarathon (Mountain)
Reihmane et al., 2013Half-Marathon: 26 ± 5 Marathon: 27 ± 522 (♂) 18 (♂)40 (♂)RECHalf-marathon Marathon
Millet et al., 201140.22222 (♂)ATLUltra-marathon 166 km
Auersperger et al., 2012Interval Group: 32.9 ± 5.7 Continuous Group: 31.6 ± 4.810 818 (♀)RECChronic Training
Bernecker et al., 201343 (33–53)1212 (♂)RECMarathon
Chimenti et al., 200940.3 ± 3.89 (♂)9 (♂)RECHalf-marathon, fall (21 km), winter (12 km) and summer (10 km)
Papassotiriou et al., 200842.8 ± 1.41515 (♂)ATLUltra-marathon 246 km
Kim et al., 200745.7 ± 5.15454 (♂)ATLUltra-marathon 200 km
Peters et al., 2004Fast group: 35.4 ± 1.84 Slow group: 41.4 ± 2.779 1030 (♂)ATLUltra-marathon 90 km
Suzuki et al., 200331.7 ± 5.01010 (♂)ATLMarathon
Bachi et al., 2015Sedentary group: 35.5 ± 7 Marathon runners: 35.7 ± 92040 (♂)20RECMarathon
Kłapcinska et al., 201345.4 ± 9.277 (♂)ATLUltra-marathon 48 h
Rehm et al., 201340.95 ± 9.381919 (14♂-5♀)RECMarathon
Fehrenbach et al., 200032.3 ± 9.31224 (♂)12RECHalf-marathon
Schobersberger et al., 200036.3 (22–50)1313 (♂)ATLUltra-marathon 67 km
Suzuki et al., 200021–391616 (♂)ATLMarathon
Vaisberg et al., 2012Sedentary Group: 37.5 ± 4 Athletes Group: 38 ± 71442 (♂)28RECMarathon
Tomaszewski et al., 2003Lean, BMI < 25 kg/m2 Marathon runners: 43.1 ± 8.4 Control: 42.5 ± 10.4 Non-lean, BMI > 25 kg/m2 Marathon runners: 45.6 ± 12.3 Control: 43.1 ± 7.555 12110 (♂)30 13ATLUltra-marathon
Bonsignore et al., 200241.3 ± 13.4Half-marathon: 8 Marathon: 825 (♂)9ATLHalf-marathon and Marathon
Nickel et al., 2012LE: 40 ± 7; LNE 40 ± 6; ONE 40 ± 6LE: 16; LNE: 1647 (♂)15ATL and RECMarathon
Waśkiewicz et al., 201243.0 ± 10.81414 (♂)ATLUltra-marathon 24 h
Chimenti et al., 2010NR1515 (♂)ATLHalf-marathon
Ng et al., 200825 (21–32)3030 (♂)NRLHalf-marathon
Siegel et al., 200749 ± 103333 (♂)NRLMarathon
Shin and Lee, 201352.8 ± 5.01818 (♂)ATLUltra-marathon 308 km
Jee and Jin, 201249.5 (47–54)2424 (♂)ATLUltra-marathon 308 km
Santos et al., 2013Athletes 35.2 ± 3.6 Non-athletes 31.6 ± 2.3Athletes: 1527 (♂)Non-athletes: 12ATLMarathon
Hewing et al., 201550.3 (22–72)167167 (78♂) and (89♀)ATLMarathon
Nieman et al., 200346.9 (33–65)3131 (22♂) and (9♀)ATLUltra-marathon 160 km
Uchakin et al., 2003WR: 37.8 ± 3.9 CT: 40.3 ± 7.7WR: 815CT: 7ATLMarathon
Mrakic-Sposta et al., 201545.04 ± 8.754646 (♂)ATLMountain Ultra-Marathon 330 km
Stuempfle et al., 2016With nausea: 44.3 ± 10.5 Without nausea: 41.8 ± 9.120(15♂-05♀)ATLUltra-Marathon 161-km
Nieman et al., 201622–4520(10♂-10♀)ATL1.5 h on treadmills at ~70% VO2max followed by 30 min of downhill running
Arakawa et al., 201652.1 ± 12.12525 (♂)ATLUltra-Marathon
Mohamed et al., 2016SS: 23.9 ± 4.20 LDR: 22.70 ± 3.70 MDR: 21 ± 1.80SS (n = 8) LDR (n = 9) MDR (n = 8)24 (♂)ATLIncremental Event (VAMEVAL test) Supra-Maximal Exhausting Race (Limited-Time Test)
Cairns and Hew-Butler, 201543.7 ± 9.8Normonatremic: 5 Hyponatremic: 1015 (12♂ 3♀)ATL100 km (103.7 km) and 100 miles (173.7 km)
Gill et al., 2015a40 ± 717(14♂-03♀)17 (04♂-08♀)ATLUltra-Marathon 24-H
Krzeminski et al., 201630 ± 1.00909 (♂)ATLUltra-Marathon 100 km
Nielsen et al., 201640 (29–56)Half-Marathon: (09♂-09♀) Marathon: (14♂)32RECHalf-Marathon/Marathon

Characteristics of the studies.

♂, male; ♀, female; EG, exercise group; CG, control group; PBMCs, peripheral blood mononuclear cells; LE, lean elite group; LNE, non-elite group; ONE, obese non-elite group; BMI, body mass index; WR, White Rock marathon; CT, CowTown marathon; SS, sedentary subjects; LDR, long-distance runners; MDR, Middle-distance runners; ALT, Athlete; REC, Recreational; NOV, Novice; Not reportable level (No reported details by authors), NRL; LNR, Level not reported.

Table 4

CitationOutcomesExercise
Pre [mean (SD)] or median (IQR)

Post [mean (SD)] or median (IQR)
Control
Pre [mean (SD)] or median (IQR)

Post [mean (SD)] or median (IQR)

p valueb
Grabs et al., 2015IL-6 (mg/L)2.0 (0.0)33.1 (24.1–37.00)a
hs-CRP (mg/L)0.83 (0.57–1.18)9.13 (6.48–13.63)a
Fallon et al., 2001CRP (mg/L)0.19 (0.14)1.84 (0.88)a
Kim et al., 2015hs-CRP (mg/L)0.06 (0.07)0.10 (0.09)a
Gill et al., 2015bCRP (mg/L)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
1.1 (1.7)
7.4 (5.3)
10.0 (5.7)
9.2 (5.9)
8.8 (5.6)
1.6 (2.4)
8.8 (5.4)
9.6 (5.9)
10.0 (6.7)a
11.0 (6.4)a
1.4 (0.7)

1.3 (0.8)b

1.3 (0.8)b
NS
<0.05
<0.05
IL-6 (pg/L)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
8.2 (4.5)
20.8 (18.5)
20.7 (16.8)
19.2 (14.1)
18.2 (11.6)
27.9 (23.4)a
20.7 (14.8)
25.3 (24.3)a
21.7 (12.6)a
23.4 (13.1)a
7.5 (2.5)

5.5 (7.1)b

6.5 (5.7)b
NS
<0.05
<0.05
IL-1β (pg/L)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
0.6 (0.3)
1.1 (0.4)
1.2 (0.4)
1.1 (0.3)
1.2 (0.4)
1.0 (0.3)a
1.1 (0.4)
1.2 (0.4)
1.4 (0.4)a
1.4 (0.4)a
0.7 (0.2)

1.2 (0.2)

1.3 (0.5)
NS
NS
NS
TNF-α (pg/L)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
3.1 (2.9)
6.1 (4.5)
6.9 (4.4)
6.5 (4.2)
7.1 (3.8)
6.3 (5.0)a
6.6 (3.7)
6.1 (3.8)a
8.1 (4.3)a
8.3 (5.0)
1.3 (0.4)

1.8 (0.7)b

2.3 (0.7)b
NS
<0.05
<0.05
IFN-γ (IU/ml)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
9.3 (5.5)
15.2 (6.8)
16.7 (6.7)
16.2 (7.2)
18.8 (10.0)
12.9 (6.0)a
16.9 (5.7)
15.2 (5.2)
19.9 (8.3)a
22.7 (9.9)a
16.8 (5.5)

14.3 (2.0)

16.8 (5.1)
NS
NS
NS
IL-10 (pg/ml)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
0.7 (0.6)
7.0 (10.8)
9.0 (10.2)
9.0 (12.2)
8.2 (11.2)
7.9 (10.1)a
7.9 (9.1)
8.0 (9.4)
9.3 (10.1)
10.9 (15.0)a
0.6 (0.1)

1.4 (0.3)b

1.4 (0.7)b
NS
<0.05
<0.05
IL-1ra (pg/ml)
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
22.9 (8.0)
39.8 (12.4)
45.5 (20.6)
37.9 (14.7)
47.1 (22.4)
70.3 (28.1)a
61.0 (39.8)a
53.9 (19.0)a
56.3 (30.4)a
63.2 (28.1)a
23.4 (7.3)

36.4 (9.2)b

33.1 (9.3)b
NS
<0.05
<0.05
Mattusch et al., 2000CRP (mg/L)1.19 (1.63)0.82 (0.94)0.77 (2.18)1.55 (9.17)NS
Neidhart et al., 2000CRP (mg/L)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
NR
NR
NR
NR
NRb,c
NRb↑,c
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NS
NS
NS
NS
<0.05
<0.05
IL-1β (ng/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NS
NS
NS
NS
NS
NS
IL-1ra (ng/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5))
95
260b↑,c
485b↑,c
1195b↑,c
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NS
<0.05
<0.05
<0.05
NS
NS
IL-6 (ng/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
1.8b
8.7c
9.8c
5.3c
2.2
2.1
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
<0.05
NS
NS
NS
NS
NS
TNF-α (pg/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
9.7
16.6c
14.3c
15.1c
13.1c
10.2c
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NS
NS
NS
NS
NS
NS
sIL-6R (pg/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
NRb
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
<0.05
NS
NS
NS
NS
NS
sTNFRII (pg/ml)
Before run (T0)
After 31 km (T1)
After 42 km (T2)
2 h after run (T3)
24 h after run (T4)
48 h after run (T5)
3180
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NS
NS
NS
NS
NS
NS
Vaisberg et al., 2013Il-6 nasal cell extract (pg/mg)
Baseline
Immediately
72 h
Symptomatic
0.07 (0.11)
0.33 (0.17)d
2.49 (2.35)d
Asymptomatic
0.22 (0.47)
0.49 (0.89)d
0.94 (1.1)d
NS
NS
NS
Il-6 serum (pg/ml)
Baseline
Immediately
72 h
8.2 (20.8)
40.9 (30.9)d
10.6 (20.4)
14.9 (32.3)
39.2 (26.5)d
16.9 (34.3)
NS
NS
NS
IL-10 nasal cell extract (pg/mg)
Baseline
Immediately
72 h
0.22 (0.30)
0.15 (0.15)
5.33 (8.00)d,e
0.28 (0.69)
1.0 (2.68)
10.26 (13.31)b,d,e
NS
NS
NS
IL-10 serum (pg/ml)
Baseline
Immediately
72 h
0.76 (0.1)b
57.2 (32.7)d
1.1 (0.9)
17.4 (34.0)
30.7 (25.3)d
4.5 (11.4)
<0.05
NS
NS
Niess et al., 2000IL-8 (pg/ml)
Baseline
0 h
3 h
24 h
48 h
TNF-α**
NR
NR↑d,b
NR
NR
NR
NR
NR
NR
NR
NR

<0.05


Kasprowicz et al., 2013CRP (ng/ml)
Baseline
25 km
50 km
75 km
Post
14 h after
NR
NR
NR
NR
NR↑d,f
NR↑d,f,g
IL-6 (pg/ml)
Baseline
25 km
50 km
75 km
Post
14 h after
NR
NR↑d
NR↑d,f
NR↑d,f
NR↑d,f
NR↓g,h,i
Saugy et al., 2013CRP (mg/dl)0.31 (0.32)13.11 (7.51)a1.05 (1.04)0.65 (0.61)b<0.05
Jee et al., 2013CRP (mg/dl)
Baseline
100 km
200 km
308 km
0.31 (0.21)
3.97 (4.58)
25.37 (18.24)d,j
NR
0.39 (0.61)
4.27 (5.75)
25.09 (14.54)d,j
22.48 (12.90)d,j
NS
NS
NS
NS
Karstoft et al., 2013CRP (mg/dl)1.0 (0.0)6.0 (1.1)a
Wilhelm et al., 2014TNF-α (pg/ml)
Baseline
Post race
Follow-up 1
Follow-up 2
NR
NR↑d
NR
NR
IL-6 (pg/ml)
Baseline
Post race
Follow-up 1
Follow-up 2
NR
NR↑d
NR
NR
hsCRP (mg/dl)
Baseline
Post race
Follow-up 1
Follow-up 2
NR
NR
NR↑d
NR
Reihmane et al., 2013IL-6 (pg/ml)–Half-marathonMarathon runners
Pre-race
15 min post-race
28 h post-race
NR
NR↑*b
NR
NR
NR
NR
TNF-α (pg/ml)–Half-marathon
Pre-race
15 min post-race
28 h post-race
NR
NR↑*b
NR
NR
NR
NR
Saravia et al., 2010THE PAPER WAS NOT AVAILABLE
Millet et al., 2011CRP (mg/dl)
Pre
Post
2 days after
5 days after
9 days after
16 days after
2.0 (0.0)
46.8 (24.8)*
30.0 (19.7)*
7.2 (3.7)*
2.5 (1.2)
2.3 (0.6)
Auersperger et al., 2012IL-6 (pg/ml)**
Hs CRP (mg/dl) – Interval
Continuos
Baseline
3 weeks of training
Recovery 1
3 weeks of training
Recovery 2
Post
0.88 (1.40)
1.13 (1.45)
0.50 (0.66)
0.98 (0.88)
0.49 (0.59)
4.85 (12.54)
1.48 (1.04)
1.27 (0.99)
1.62 (2.92)
1.60 (1.52)
1.92 (2.99)
1.01 (1.28)
Bernecker et al., 2013IL-6 (ng/L)2.06 (1.98–2.20)31.93 (20.68–41.47)a
TNF-α (ng/L)9.01 (7.16–10.26)10.26 (9.33–12.31)a
Chimenti et al., 2009IL-8 (ng/ml)–Fall
Baseline
Race
NR
NR
TNF-α (pg/ml)–Fall
Baseline
Race
NR
NR
IL-8 (ng/ml)–Winter
Baseline
Race
NR
NR
TNF-α (pg/ml)–Winter
Baseline
Race
NR
NR
IL-8 (ng/ml)–Summer
Baseline
Race
NR
NR
TNF-α (pg/ml)–Summer Baseline
Race
NR
NR
Papassotiriou et al., 2008CRP (mg/L)
Baseline
End of race
48 h post
0.8 (0.1)
93.0 (12.6)d
70.6 (11.5)d,k
IL-6 (ng/L)
Baseline
End of race
48 h post
0.8 (0.1)
8376.0 (1819.8)d
0.7 (0.1)d,k
TNF-α (ng/L)
Baseline
End of race
48 h post
3.9 (0.9)
4.0 (0.8)d
3.7 (0.7)d,k
Kim et al., 2007Hs CRP (IU/L)
Pre
100 km
200 km
2.0 (4.0)
6.0 (6.0)*
46.0 (28.0)*,j
IL-6 (pg/ml)
Pre
100 km
200 km
0.86 (0.17)
104.3 (45.5)
108.6 (28.4)j
TNF-α
Pre
100 km
200 km
2.35 (1.56)
2.60 (1.43)
2.77 (1.82)
Peters et al., 2004CRP (mg/l)–Well trainedNRNR↑aLess trained
NR
NR↑a
Suzuki et al., 2003TNF-α (pg/ml)
Plasma
Urine**
0.31 (0.44)0.29 (0.38)
IL1-β (pg/ml)
Plasma
Urine
0.43 (0.27)
1.7 (3.7)
0.52 (0.23)
7.1 (5.1)a
IL-6 (pg/ml)
Plasma
Urine
1.27 (1.19)
2.86 (6.91)
101.40 (50.34)a
23.60 (19.94)
IL-8 (pg/ml)
Plasma
Urine**
1.16 (0.70)0.06 (6.95)a
IL-10 (pg/ml)
Plasma
Urine
8.0 (2.1)
19.3 (6.3)
32.8 (14.5)a
22.8 (3.8)a
Bachi et al., 2015IL-8 (pg/ml) PBMCs
Baseline
Post
72 h post
NR↑b
NR
NR↓d
NR
NR
NR
IL-8 (pg/ml) serum
Baseline
Post
72 h post
NR
NR↑d
NR↓l
NR
NR
NR
IL-10 (pg/ml) PBMCs
Baseline
Post
72 h post
NR↑b
NR
NR↓d
NR
NR
NR
IL-10 (pg/ml) serum
Baseline
Post
72 h post
NR
NR↑d
NR↓l
NR
NR
NR
Kłapcinska et al., 2013CRP (mg/l)
Baseline
12 h running
24 h running
48 h running
24 h post-race
48 h post-race
0.8 (0.8)
3.4 (17.7)d
30.0 (8.9)d
63.5 (31.5)d
45.5 (37.8)d
28.0 (38.2)d
IL-6 (pg/ml)
Baseline
12 h running
24 h running
48 h running
24 h post-race
48 h post-race
0.64 (0.34)
35.86 (17.35)d
33.25 (16.54)d
23.20 (18.85)d
7.39 (13.32)d
2.19 (3.67)
Rehm et al., 2013sIFNγ (x1.000) pg/ml
Baseline
Pre-race
Recovery
42.24 (26.75)
28.86 (23.16)d
38.86 (28.76)
sIL4 pg/ml
Baseline
Pre-race
Recovery
3.59 (5.08)
8.65 (10.71)d,m
4.02 (6.06)
sIL10 pg/ml
Baseline
Pre-race
Recovery
389.73 (254.22)
248.9 (191.8)d
323.79 (240.5)
Fehrenbach et al., 2000IL-8 pg/ml
Baseline
0 h
3 h
24 h
5.0 (6.5)
30.7 (5.3)d
8.9 (11.3)
3.9 (6.3)
TNF-α pg/ml
Baseline
0 h
3 h
24 h
0.3 (0.2)
1.2 (0.9)
0.6 (0.6)
0.3 (0.5)
Schobersberger et al., 2000IL-6 pg/ml
Baseline
0 h
2 h
Day1
Day3
Day5
0.0 (0–1.75)
60.0 (40.5–180.0)d
65.0 (22.3–81.0)d
0.0 (0.0–5.0)
0.0 (0.0–0.8)
0.0 (0.0–4.0)
IL1-ra pg/ml
Baseline
0 h
2 h
Day1
Day3
Day5
23.0 (18.0–33.5)
720.0 (370.0–42.01)d
733.0 (443.0–41.63)d
100.0 (43.0–221.0)d
84.0 (25.0–246.0)
28.0 (17.0–215.0)
TNF-α pg/ml
Baseline
0 h
2 h
Day1
Day3
Day5
13.0 (10.3–15.0)
17.5 (15.0–30.0)d
18.0 (14.3–24.8)d
16.5 (12.8–28.0)d
16.2 (11.0–17.5)d
16.0 (12.0–20.0)d
sTNF-RI ng/ml
Baseline
0 h
2 h
Day1
Day3
Day5
2.4 (2.1–2.9)
5.7 (4.5–11.7)d
6.2 (4.2–9.0)d
3.9 (3.2–5.3)d
3.5 (2.8–5.0)d
2.8 (2.3–3.7)d
sTNF-RII ng/ml
Baseline
0 h
2 h
Day1
Day3
Day5
11.1 (7.2–13.9)
11.8 (10.4–22.4)d
12.9 (10.6–21.3)d
15.7 (10.4–19.7)d
15.1 (9.8–19.9)d
11.6 (8.1–17.7)d
Suzuki et al., 2000IL-1β pg/ml
IL1-ra pg/ml
IL-2 pg/ml
IL-4 pg/ml
IL-6 pg/ml
IL-8 pg/ml
IL-10 pg/ml
IL-12 pg/ml**
TNF-α pg/ml**
IFN-α pg/ml**
IFN-γ pg/ml
1.8 (3.6)
59.0 (37.0)
73.0 (44.0)
3.5 (1.45)
<1.1 (1.3)
22.0 (19)
13.9 (12.3)



1.5 (0.8)
1.4 (2.1)
12629.0 (12360.0)a
50.0 (49.0)a
4.9 (4.1)
120.0 (79.0)a
5.5 (25.0)a
47.9 (23.1)a



1.4 (1.0)
Vaisberg et al., 2012IL-6 pg/ml
Baseline
Immediatly
72 h
NR
NRd,n
NR
NR

NS
NS
NS
TNF-α
Baseline
Immediatly
72 h
NRb
NRd,n
NR
NR

<0.05
NS
NS
Tomaszewski et al., 2003 (64)CRP mg/L0.3 (0.2–0.7)1.8 (1.0–3.4)a
Bonsignore et al., 2002TNF-α pg/ml–Half-marathonTNF-α pg/ml–Marathon
Baseline
End of raced
Post
NR
NR
NR
NR
NR
NR
IL-6 pg/ml–Half-marathonIL-6 pg/ml–Marathon
Baseline
End of raced
Post
NR
NRd,b
NR
NR
NR
NR
NS
NS
NS
Tomaszewski et al., 2003CRP mg/dl–Lean Elite
Baseline
Marathond
24 hd
CRP mg/dl–Lean Non-elite
NR
NRd
NRd
Obese non-elite
NR
NRd
NRdb(in relation to Lean Elite)↑
IL-6 pg/ml–Lean Elite
Baseline
Immediately post marathond
24 hd↑,e
IL-6 pg/ml–Lean non-elite
NRb(in relation Lean Elite)↑
NRd
NRd↑,e
Obese non-elite
NRb(in relation to Lean Elite)↑
NRd
NRd↑,e
TNF-α pg/ml–Lean Elite
Baseline
Immediately post marathon
24 hd↑,e
TNF-α pg/ml–Lean Non-elite
NR
NR
NRd↑,e
Obese non-elite
NR
NR
NRd↑,e
IL-10 pg/ml–Lean Elite
Baseline b(in relation to obese non-elite)↓
Immediately post marathon d
24 he
IL-10 pg/ml–Lean Non-elite
NR b(in relation to obese non-elite)↓
NRd
NRe
Obese non-elite
NR
NRd
NRe
Waśkiewicz et al., 2012IL-6 mg/dL
Baseline
Immediately post Marathon
Post 12 h
Post 24 h
0.87 (0.68)
20.29 (7.77)d
27.36 (7.67)d
28.49 (11.99)d
hsCRP mg/dL
Baseline
Immediately post Marathon
Post 12 h
Post 24 h
1.7 (2.7)
1.7 (2.5)
8.7 (4.6)d
39.2 (16.7)d
Chimenti et al., 2010IL-8 ng/ml–Octuber
IL-8 ng/ml–May
IL-8 ng/ml–November
NR
NR
NR
NRa
NRa
NRa
Ng et al., 2008IL-6 pg/ml
IL-10 pg/ml
IL-1ra
TNF-α pg/ml
IL1-β
9.2 (4.1)a
6.4 (2.4)a
154.1 (0.4)
NR
NR
15.2 (5.3)
9.6 (3.0)
189.8 (61.9)
NR
NR
Siegel et al., 2007IL-6 pg/mL
Baseline
2 h post race
24 h post race
1.6 (0.45)
66.6 (11.9)d
4.3 (0.6)
CRP ng/dL
Baseline
2 h post race
24 h post race
0.10 (0.02)
0.10 (0.03)
2.3 (0.53)d
Shin and Lee, 2013CRP IU/L
Baseline
100 km
200 km
308 km
NR
NRd
NRd
NRd
IL-6 pg/ml
Baseline
100 km
200 km
308 km
NR
NRd
NRd
NRd
IL-10 pg/ml
Baseline
100 km
200 km
308 km
NR
NRd
NRd
NRd
IL-8 pg/ml
Baseline
100 km
200 km
308 km
NR
NRd
NRd
NRd
Jee and Jin, 2012hsCRP IU/L
Baseline
100 km
200 km
308 km
0.40 (0.10)
5.06 (1.46)d
25.56 (3.82)d,i
21.87 (3.49)d,i
TNF-α pg/ml
Baseline
100 km
200 km
308 km
3.68 (0.15)
4.00 (0.20)
3.37 (0.18)i
4.50 (0.36)d,o
Santos et al., 2013IL-6 pg/ml
IL1-ra pg/ml
TNF-α pg/ml
IL-8 pg/ml**
IL-10 pg/ml**
CRP UL
106.00 (38.5)
18.0 (12.0)
32.3 (13.3)


5.2 (0.5)
435.0 (145.5)a
2708.0 (355.0)a
32.4 (7.7)
40.4 (20.2)
32.0 (11.2)
5.3 (0.7)
Hewing et al., 2015CRP mg/dl
Baseline
Post
14 days lates
0.10 (0.05–0.21)
0.06 (0.04–0.12)d
0.10 (0.06–0.18)
Nieman et al., 2003IL-10 pg/ml
Baseline
90 km
160 km
4.65 (0.40)
39.7 (8.0)d
49.0 (8.2)d
IL1-ra pg/ml
Baseline
90 km
160 km
229.0 (14.0)
2330.0 (421.0)d
1616.0 (255.0)d
IL-6 pg/ml
Baseline
90 km
160 km
1.19 (0.15)
58.6 (4.6)d
60.9 (9.4)d
IL-8 pg/ml
Baseline
90 km
160 km
6.31 (1.09)
20.4 (2.1)d
22.0 (2.4)d
Uchakin et al., 2003IL-2 (IU/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
6.0 (2.5)
2.0 (0.4)d
1.6 (0.2)d
6.6 (1.0)
5.0 (0.6)
8.4 (1.2)d
5.7 (1.0)
INF-γ (IU/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
210.8 (26.6)
17.7 (3.5)d
14.4 (3.3)d
196.4 (15.8)
154.8 (20.0)
272.8 (23.9)d
141.0 (18.1)
IL-10 (pg/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
445.3 (69.3)
310.0 (44.3)
463.7 (146.9)
262.3 (27.0)
288.2 (33.2)
441.8 (73.9)
355.0 (47.9)
TNF-α (pg/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
16937.0 (1800.8)
9594.0 (1421.5)d
1394.0 (1522.8)d
12859.0 (1585.0)d
12899.0 (1720.8)d
12276.0 (12276.7)d
14043.0 (1231.2)
IL1-β (pg/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
4377.1 (664.5)
2937.1 (696.8)
3162.9 (617.1)
3520.0 (743.3)
2342.8 (359.6)d
2388.6 (481.9)d
2817.1 (243.6)
IL-6 (pg/ml)
Baseline
0 h
1 h
24 h
48 h
5 days
8 days
16571.4 (2058.1)
13585.7 (3105.4)
16200.0 (1740.2)
6514.3 (985.0)d
8414.3 (1470.9)d
10642.8 (2291.1)
14271.4 (1331.8)
Mrakic-Sposta et al., 2015IL-6 (pg/ml) Plama
IL-6 (pg/ml) Urine
1.29 ± 0.54
0.71 ± 0.17
66.42 ± 36.92a
1.33 ± 0.56a
Stuempfle et al., 2016IL-6 (pg/ml)
CRP (ng/ml)
Without Nausea
0.9 ± 0.4
323 ± 487
Without Nausea
105.7 ± 53.6a
31,448 ± 13,149a
With Nausea
1.0 ± 0.7
1686 ± 2607
With Nausea
78.6 ± 62.5a
46,361 ± 29,708a
NS
NS
Nieman et al., 2016IL-6 (pg/ml)
Pre-run
Post-run
1-h Post-run
24-h Post run
IL-8 (pg/ml)
Pre-run
Post-run
1-h Post-run
24-h Post run
IL-10 (pg/ml)
Pre-run
Post-run
1-h Post-run
24-h Post run
IL-1ra (pg/ml)
Pre-run
Post-run
1-h Post-run
24-h Post run
CRP (mg/l)
Pre-run
Post-run
1-h Post-run
24-h Post run
Male
3.17 ± 0.41
11.8 ± 2.23*
9.03 ± 1.41*
2.36 ± 0.31
9.99 ± 1.00
22.4 ± 2.9*
18.1 ± 1.5*
8.12 ± 0.50
2.50 ± 0.18
9.33 ± 1.77*
10.5 ± 1.9*b
2.51 ± 0.53
111 ± 10.8
216 ± 14.8
385 ± 83.8
111 ± 9.8
0.71 ± 0.15
0.67 ± 0.17
0.62 ± 0.16
2.56 ± 0.50*
Female
2.88 ± 0.91
7.46 ± 0.89
7.37 ± 1.56
2.99 ± 1.19
8.88 ± 0.68
16.1 ± 1.1
16.6 ± 2.1
9.17 ± 0.68
3.31 ± 0.64
6.20 ± 0.91
6.03 ± 0.81
3.51 ± 0.81
125 ± 18.4
215 ± 40.5
300 ± 80.4
117 ± 9.3
0.70 ± 0.19
0.71 ± 0.22
0.70 ± 0.19
2.02 ± 0.73
Arakawa et al., 2016IL-6 (pg/ml)
Baseline
Day 1
Day 2
Day 3
Day 5
Day 7
CRP (mg/dl)
Baseline
Day 1
Day 2
Day 3
Day 5
Day 7
TNF-α (pg/ml)
Baseline
Day 1
Day 2
Day 3
Day 5
Day 7
0.77 ± 0.26
26.52 ± 5.05d
19.28 ± 1.99d
3.35 ± 0.96
6.53 ± 4.16
1.40 ± 0.38
0.07 ± 0.03
0.07 ± 0.03
0.72 ± 0.14d
1.45 ± 0.29d
0.64 ± 0.18
0.57 ± 0.28
0.91 ± 0.06
0.95 ± 0.09
0.84 ± 0.06
0.95 ± 0.08
0.98 ± 0.07
1.15 ± 0.17
Mohamed et al., 2016IL-6 (pg/ml)
VAMEVAL test
Before
After
IL-6 (pg/ml)
Limited-time test
Before
After
TNF-α (pg/ml)
VAMEVAL test
Before
After
TNF-α (pg/ml)
Limited-time test
Before
After
Sedentary Subjects
NR
NRd
NR
NRd,b
NR
NRd
NR
NRd
Long-Distance Runners
NR
NRd
NR
NRd
NR
NRd
NR
NRd
Middle-Distance Runners
NR
NRd
NR
NRd
NR
NRd
NR
NRd
Cairns and Hew-Butler, 2015IL-6 (pg/ml)
Before
After
With hyponatremia
0.1 ± 0.2
10.6 ± 6.1*
Non-hyponatremia
0.5 ± 0.4
8.4 ± 2.8*
Gill et al., 2015aIL-6 (pg/ml)
Before
After
IL-1β (pg/ml)
Before
After
TNF-α (pg/ml)
Before
After
IFN-γ (pg/ml)
Before
After
IL-10 (pg/ml)
Before
After
IL-8 (pg/ml)
Before
After
0.4 (0.3 to 0.5)
14.5 (9.3 to 19.7)*
0.1 (0.0 to 0.3)
0.6 (0.1 to 1.1)*
2.8 (2.5 to 3.2)
3.8. (3.5 to 4.2)*
1.0 (0.6 to 1.4)
1.2 (0.3 to 2.2)
2.1 (1.3 to 2.9)
12.8 (7.3 to 18.2)*
11.4 (9.4 to 13.4)
38.7 (26.3 to 51.1)*
Krzeminski et al., 2016TNF-α (pg/ml)
Pre-race
Post-race
90 min post-race
IL-6 (pg/ml)
Pre-race
Post-race
90 min post-race
IL-10 (pg/ml)
Pre-race
Post-race
90 min post-race
IL-18 (pg/ml)
Pre-race
Post-race
90 min post-race
IL-1β (pg/ml)
Pre-race
Post-race
90 min post-race
1.39 ± 0.09
1.63 ± 0.09*
1.54 ± 0.09
0.54 ± 0.07
47.35 ± 8.48*
37.67 ± 7.94*l
0.31 ± 0.06
5.04 ± 1.34*
1.24 ± 0.35*
75.08 ± 9.46
96.74 ± 9.92*
101.25 ± 9.28
0.76 ± 0.24
1.30 ± 0.27
0.70 ± 0.12
Nielsen et al., 2016IL-1β (pg/ml)
Pre-race
Post-race
Il-6 (pg/ml)
Pre-race
Post-race
IL-8 (pg/ml)
Pre-race
Post-race
IL-10 (pg/ml)
Pre-race
Post-race
TNF-α (pg/ml)
Pre-race
Post-race
IFN-γ (pg/ml)
Pre-race
Post-race
Marathon
NR
NR
NR
NR*
NR
NR*
NR
NR*
NR
NR
NR
NR
Half-Marathon
NR
NR
NR
NR*
NR
NR*
NR
NR
NR
NR
NR
NR

Summary of outcome measures.

NS, not significant; –, not compared or evaluated;

**

, below the detectable plasma concentrations; NR, not reported; PBMCs, produced by peripheral blood mononuclear cells; IL-6, interleukin 6; CRP, C-reactive protein; IL-8, interleukin- eight; IL-2, interleukin two; IL-4, interleukin four; IL-10, interleukin tem; IL-12, interleukin 12; IFN-γ, interferon gama; TNF-α, turmor necroses factor alpha; IL1-ra, receptor antogonist of interleukin one; IL1-β, interleukin beta; sTNF-R, soluble receptor for turmor necroses factor alpha; sIL6-R, soluble receptor antagonista for interleukin six; 0 h, immediately post-race;

Significant difference (p < 0.05) vs. pre-stage 1;

*

Significant difference (p < 0.05) vs. pre;

a

Significant difference (p < 0.05) between pre and post for the same group;

b

Significant difference (p < 0.05) between groups;

c

Significant difference (p < 0.05) vs. T0;

d

Significant difference (p < 0.05) vs. baseline;

e

Significant difference (p < 0.05) vs. immediately;

f

Significant difference (p < 0.05) vs. 25 km;

g

Significant difference (p < 0.05) vs. 50 km;

h

Significant difference (p < 0.05) vs. 75 km;

i

Significant difference (p < 0.05) vs. post;

j

significant difference (p < 0.05) vs. 100 km;

k

Significant difference (p < 0.05) vs. end of race;

l

Significant difference (p < 0.05) vs. post;

m

Significant difference (p < 0.05) vs. recovery;

n

Significant difference (p < 0.05) vs. 72 h;

o

Significant difference (p < 0.05) vs. 200 km.

The 51 studies included resulted in a total of 1,421 subjects, of whom 163 were female and 1,234 males; 24 subjects were not identified by sex in one study (Neidhart et al., 2000). All trials provided age ranges for the subjects and the mean age was 39.16 years.

The common protocols adopted included marathon in 17 studies, ultra-marathon in 22, half-marathon in three studies, different distance protocols (42.195, 21.1, 12, 10 km and treadmill) in seven studies, and chronic training only in two studies (see Table 3).

Discussion

The aim of this systematic review was to analyze studies that verified the effects of different endurance running exercises on acute and chronic inflammatory responses in runners of different training background. The present systematic review allows an initial understanding of this issue. It seems that acute and chronic endurance running may affect anti- and pro-inflammatory markers. However, important differences between studies in terms of methods as well as in runners' charactersitics do not allow appropriate comparison or generalization of results.

Inflammatory markers

The timing in data collection could be considered an important limiting factor for adequate comparisons, given the heterogeneity observed across the reported acute (i.e., 5–20 min) (Fallon et al., 2001; Kim et al., 2007; Vaisberg et al., 2013; Grabs et al., 2015) and delayed responses (24 h to 8 days) (Uchakin et al., 2003; Siegel et al., 2007; Hewing et al., 2015). This is not a simple issue given the different kinetics and biological availability of the molecules considered as IL-6 and CRP (Kasprowicz et al., 2013; Reihmane et al., 2013). Of note, some inflammatory markers (e.g., monocyte chemoattractant protein-1, granulocyte colony-stimulating factor) (Suzuki et al., 2003) have not been included in the current review. Further studies should elaborate appropriate study designs that consider both the appropriateness of the inflammatory markers selected as well as their kinetics.

Runners' and training load characteristics

Another important confounding factor is the different experience of runners. Thus, 26 studies (4 studies with male and female participants, and 15 studies with only male participants) reported a range of 4–17.5 years of experience with competitions (e.g., marathon, and ultra-marathon experience) (Schobersberger et al., 2000; Fallon et al., 2001; Nieman et al., 2003, 2016; Suzuki et al., 2003; Tomaszewski et al., 2003; Kim et al., 2007, 2015; Millet et al., 2011; Jee and Jin, 2012; Vaisberg et al., 2012, 2013; Waśkiewicz et al., 2012; Bernecker et al., 2013; Jee et al., 2013; Karstoft et al., 2013; Kasprowicz et al., 2013; Kłapcinska et al., 2013; Saugy et al., 2013; Shin and Lee, 2013; Wilhelm et al., 2014; Grabs et al., 2015; Hewing et al., 2015; Mrakic-Sposta et al., 2015; Krzeminski et al., 2016; Mohamed et al., 2016). However, 25 studies did not report this information (Fehrenbach et al., 2000; Mattusch et al., 2000; Neidhart et al., 2000; Niess et al., 2000; Suzuki et al., 2000; Bonsignore et al., 2002; Uchakin et al., 2003; Peters et al., 2004; Siegel et al., 2007; Ng et al., 2008; Papassotiriou et al., 2008; Chimenti et al., 2009, 2010; Auersperger et al., 2012; Nickel et al., 2012; Rehm et al., 2013; Santos et al., 2013; Bachi et al., 2015; Gill et al., 2015b; Arakawa et al., 2016; Nielsen et al., 2016; Stuempfle et al., 2016; Vernillo et al., 2017). This is not a trivial issue given that training experience of runners could have a potentially additive effect to the influence of runners' age on inflammation that warrants further research. Besides, only 34 articles especified the training preparation (km/week that ranged between 21.4 and 161 and time that ranged between 3.9 and 10 h/week) of runners before races (Fehrenbach et al., 2000; Mattusch et al., 2000; Niess et al., 2000; Suzuki et al., 2000, 2003; Fallon et al., 2001; Bonsignore et al., 2002; Nieman et al., 2003, 2016; Tomaszewski et al., 2003; Uchakin et al., 2003; Peters et al., 2004; Chimenti et al., 2009; Millet et al., 2011; Auersperger et al., 2012; Jee and Jin, 2012; Nickel et al., 2012; Vaisberg et al., 2012, 2013; Waśkiewicz et al., 2012; Bernecker et al., 2013; Karstoft et al., 2013; Kłapcinska et al., 2013; Rehm et al., 2013; Reihmane et al., 2013; Santos et al., 2013; Shin and Lee, 2013; Wilhelm et al., 2014; Bachi et al., 2015; Grabs et al., 2015; Hewing et al., 2015; Mrakic-Sposta et al., 2015; Arakawa et al., 2016; Krzeminski et al., 2016). Furthermore, only two studies cited the control of intensity during training (Mattusch et al., 2000; Auersperger et al., 2012). This aspect would be important for a better understanding of the relationship between running and inflammation from a dose-response perspective. For instance, higher values for IL-6 after a limited-time test were observed in sedentary individuals when compared to long- and middle-distance runners, but with no differences between groups for TNF-α (Mohamed et al., 2016). Given the growing popularity of races that last various days, further studies are warranted to elucidate if chronic exposure to high volumes of endurance running are detrimental for health. From an evolutionary perspective, this is an interesting topic given that daily running volumes of modern hunter-gatherers are far below (e.g., ~10–15 km) (O'Keefe et al., 2010; Boullosa et al., 2013) the training and competitive volumes of runners competing in ultra-endurance events. In addition, another new aspect that must be raised in further studies is the imbalance between training phases and recovery not reported in the studies included in this systematic review. Thus, since functional overreaching might be related to inflammation (Steinacker et al., 2004), further studies should explore these relationship in conjunction with other biological markers of overreaching.

Another important characteristic for a better characterization of runners is their fitness level. For instance, maximum oxygen consumption (VO2max), which is the gold standard for aerobic evaluation, has been reported only in 14 articles (3 studies with participants of both sexes (Nieman et al., 2003, 2016; Ng et al., 2008; Chimenti et al., 2009; Jee et al., 2013), and 11 studies with males (Millet et al., 2011; Jee and Jin, 2012; Waśkiewicz et al., 2012; Kłapcinska et al., 2013; Shin and Lee, 2013; Wilhelm et al., 2014; Kim et al., 2015; Krzeminski et al., 2016; Mohamed et al., 2016). The participants of these studies could be considered recreational runners when classified by their actual VO2max (44–51 and 35–41 mL.kg-1.min-1, for males and females, respectively) (Martin and Coe, 2007). In contrast, no study included elite runners when classified by their actual VO2max (70–85 mL.kg-1.min-1 and 61–73 mL.kg-1.min-1 for males and females respectively) (Martin and Coe, 2007). Moreover, runners' classification in the current review has been challenging when using the selected criteria (see Table 3) (Stirling and Kerr, 2006; MeSH, 2015). Thus, further studies should provide all these informations for a better characterization of runners. As we did not perceive an influence of aerobic fitness on inflammatory markers, further studies should elaborate on this relationship while controlling other runners' characteristics as training experience. Additionally, the influence of other fitness components as muscle strength capacity should be assessed in further studies for verifying the potentially protective effect for muscle damage and therefore on inflammation.

Another important limitation for generalization of the results refers to the heterogeneity of running exercises (e.g., distance, intensity) used for evaluation of acute inflammatory responses. Furthermore, ambient characteristics (e.g., altitude, temperature) and race profile (e.g., uphill and downhill running) which have been suggested to influence muscle contraction and physiological responses (Vernillo et al., 2017), have not been always reported (Millet et al., 2011; Saugy et al., 2013). These aspects should be controlled in further studies for isolating the relative effect of every specific factor on inflammation.

Body fatness and inflammation

Given the relationship between adipose tissue and inflammation (Pedersen and Febbraio, 2012), attention should be paid to overweight and obese runners. For instance, a higher level of CRP 24 h following a marathon has been observed in obese non-elite runners when compared to lean elite runners (Nickel et al., 2012). Furthermore, obese non-elite runners when compared to lean elite and lean non-elite runners demonstrated a higher level of IL-6 and a lower level of IL-10 serum levels at baseline (Nickel et al., 2012). However, all groups presented an increase for serum IL-10 and TNF-α, and a decrease for serum IL-6 levels, immediately post-marathon (Nickel et al., 2012). It must be considered that increments in IL-10 induced by exercise may be responsible for the elevation in IL1-ra which exerts an anti-inflammatory action by antagonizing IL-1 and IL-1β (Dinarello, 2000; Moldoveanu et al., 2001; Petersen and Pedersen, 2005; Pedersen, 2011). Nevertheless, it could be suggested that, in overweighted individuals, a higher pro-inflammatory status at baseline and post-marathon could be observed, with unknow consequences for health in the long term.

Inflammation and cardiovascular health

One relevant issue refers to the link between inflammation and cardiovascular health. Interestingly, the exercise-induced increase of IL-6 after the marathon in 20 lean male runners was associated with a lower prevalence of arrhythmias during and after the marathon race (Grabs et al., 2015). When produced by muscle contraction, IL-6 stimulates the synthesis of other anti-inflammatory cytokines such as IL-1ra and IL-10, thus providing an inhibitory effect on pro-inflammatory cytokines such as IL-1β and TNF-α (Pedersen and Febbraio, 2012; Pedersen, 2013). However, CRP, a strong predictor of cardiovascular events, is an acute phase protein synthesized in the liver by the stimulation of IL-6 (Ridker et al., 2002). Chronic endurance training may decrease CRP values, especially when accompanied by a loss in fat mass, therefore promoting further reduction of risk for cardiovascular events (Fallon et al., 2001; Tomaszewski et al., 2003; Walsh et al., 2011; Grabs et al., 2015; Kim et al., 2015). Of note, CRP may be more susceptible to chronically decrease in individuals presenting higher baseline levels (Barnett et al., 2005). Therefore, caution should be taken when evaluating the anti- and pro-inflammatory effects of running in individuals with different characteristics regarding cardiovascular risk factors (e.g., body composition) (Moldoveanu et al., 2000; Petersen and Pedersen, 2005; Walsh et al., 2011).

Studies' characteristics

Most studies included in this systematic review were acute interventions (49 studies). However acute changes in inflammatory markers might not be related with anti- and pro-inflammatory outcomes during chronic aerobic training interventions. For instance, there were divergent responses for CRP changes in chronic interventions (Mattusch et al., 2000; Auersperger et al., 2012). Thus, while Mattusch et al. (2000) observed a reduction in CRP levels, Auersperger et al. (2012) did not observe any change. Therefore, further studies must consider this important limitation, while providing training load charactersitics as volume, intensity, and frequency of training sessions. An important question to be answered refers to the minimal training load required for runners of different levels when preparing different competitive distances, while analyzing the impact of these factors on inflammatory markers. Additionally, there is a prevalence of male runners on literature therefore more studies with female runners are needed.

Conclusion

In summary, our results revealed that acute and chronic endurance running may affect anti- and pro-inflammatory markes but methodological differences between studies do not allow comparisons or generalization of the results. Only two studies were chronic interventions. There are no studies with elite athletes. Thus, RCTs are urgently needed to identify the appropriate dose of endurance running (volume, intensity, and frequency) required to elicit improvements in inflammatory markers in runners of different levels and training background. External (e.g., ambient characteristics, race profile) and internal factors (e.g., fitness level, training experience) to runners should be considered in further studies for a better understanding of the relationship between running and the mediators of inflammation. The information provided in this systematic review would help practitioners for better designing further studies while providing reference values for a better understanding of inflammatory responses after different running events.

Statements

Author contributions

Conception and design: EB, CC, ON, JP, and DB. Search: EB, DN, and FS. Eligibility and outcome measures: EB and DN. Quality assessment: DN and JP. Writing of the manuscript: EB, DN, JP, ON, CC, and DB. Revision and approval of the final manuscript version and interpretation of the results: EB, DN, JP, ON, CC, FS, and DB.

Acknowledgments

The first and second authors would like to thank the support of their families (Rita and Nicolas).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

1.^World Health Organization; Available online at: http://www.who.int/maternal_child_adolescent/topics/adolescence/dev/en/ (Acessed November 1, 2015).

References

  • 1

    AbbasiA.FehrenbachE.HauthM.WalterM.HudemannJ.WankV.et al. (2013). Changes in spontaneous and LPS-induced ex vivo cytokine production and mRNA expression in male and female athletes following prolonged exhaustive exercise. Exerc. Immunol. Rev.19, 828.

  • 2

    ArakawaK.HosonoA.ShibataK.GhadimiR.FukuM.GotoC.et al. (2016). Changes in blood biochemical markers before, during, and after a 2-day ultramarathon. Open Access J Sports Med. 7, 4350. 10.2147/OAJSM.S97468

  • 3

    AuerspergerI.KnapB.JerinA.BlagusR.LainscakM.SkitekM.et al. (2012). The effects of 8 weeks of endurance running on hepcidin concentrations, inflammatory parameters, and iron status in female runners. Int. J. Sport Nutr. Exerc. Metab.1, 5563. 10.1123/ijsnem.22.1.55

  • 4

    BachiA. L.RiosF. J.VaisbergP. H.MartinsM.de SáM. C.VictorinoA. B.et al. (2015). Neuro-immuno-endocrine modulation in marathon runners. Neuroimmunomodulation22, 196202. 10.1159/000363061

  • 5

    BarnettA. G.van der PolsJ. C.DobsonA. J. (2005). Regression to the mean: what it is and how to deal with it. Int. J. Epidemiol. 34, 215220. 10.1093/ije/dyh299

  • 6

    BerneckerC.ScherrJ.SchinnerS.BraunS.ScherbaumW. A.HalleM. (2013). Evidence for an exercise induced increase of TNF-alpha and IL-6 in marathon runners. Scand. J. Med. Sci. Sports23, 207214. 10.1111/j.1600-0838.2011.01372.x

  • 7

    BonsignoreM. R.MoriciG.SantoroA.PaganoM.CascioL.BonannoA.et al. (2002). Circulating hematopoietic progenitor cells in runners. J. Appl. Physiol.93, 16911697. 10.1152/japplphysiol.00376.2002

  • 8

    BoullosaD. A.AbreuL.Varela-SanzA.MujikaI. (2013). Do olympic athletes train as in the Paleolithic era?Sports Med.43, 909917. 10.1007/s40279-013-0086-1

  • 9

    BrambleD. M.LiebermanD. E. (2004). Endurance running and the evolution of Homo. Nature432, 345352. 10.1038/nature03052

  • 10

    CairnsR. S.Hew-ButlerT. (2015). Incidence of exercise-associated hyponatremia and its association with nonosmotic stimuli of arginine vasopressin in the GNW100s ultra-endurance marathon. Clin. J. Sport Med. 25, 347354. 10.1097/JSM.0000000000000144

  • 11

    ChiampasG. T.GoyalA. V. (2015). Innovative operations measures and nutritional support for mass endurance events. Sports Med. 45, 6169. 10.1007/s40279-015-0396-6

  • 12

    ChimentiL.MoriciG.PaternoA.BonannoA.VultaggioM.BelliaV.et al. (2009). Environmental conditions, air pollutants, and airway cells in runners: a longitudinal field study. J. Sports Sci. 27, 925935. 10.1080/02640410902946493

  • 13

    ChimentiL.MoriciG.PaternòA.SantagataR.BonannoA.ProfitaM.et al. (2010). Bronchial epithelial damage after a half-marathon in nonasthmatic amateur runners. Am. J. Physiol. Lung Cell. Mol. Physiol. 298, L857L862. 10.1152/ajplung.00053.2010

  • 14

    DinarelloC. A. (2000). The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343, 732734. 10.1056/NEJM200009073431011

  • 15

    DownsS. H.BlackN. (1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Commun. Health52, 377384. 10.1136/jech.52.6.377

  • 16

    FallonK. E.FallonS. K.BostonT. (2001). The acute phase response and exercise: court and field sports. Br. J. Sports Med.35, 170173. 10.1136/bjsm.35.3.170

  • 17

    FebbraioM. A.PedersenB. K. (2005). Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?Exerc. Sport Sci. Rev. 33, 114119. 10.1097/00003677-200507000-00003

  • 18

    FehrenbachE.NiessA. M.SchlotzE.PassekF.DickhuthH. H.NorthoffH. (2000). Transcriptional and translational regulation of heat shock proteins in leukocytes of endurance runners. J. Appl. Physiol.89, 704710.

  • 19

    GillS. K.HankeyJ.WrightA.MarczakS.HemmingK.AllertonD. M.et al. (2015a). The impact of a 24-h ultra-marathon on circulatory endotoxin and cytokine profile. Int. J. Sports Med.36, 688695. 10.1055/s-0034-1398535

  • 20

    GillS. K.TeixeiraA.RamaL.PrestesJ.RosadoF.HankeyJ.et al. (2015b). Circulatory endotoxin concentration and cytokine profile in response to exertional-heat stress during a multi-stage ultra-marathon competition. Exerc. Immunol. Rev.21, 114128.

  • 21

    GleesonM. (2007). Immune function in sport and exercise. J. Appl. Physiol.103, 693699. 10.1152/japplphysiol.00008.2007

  • 22

    GrabsV.PeresT.ZelgerO.HallerB.PresslerA.BraunS.et al. (2015). Decreased prevalence of cardiac arrhythmias during and after vigorous and prolonged exercise in healthy male marathon runners. Am. Heart J. 170, 149155. 10.1016/j.ahj.2015.04.001

  • 23

    HewingB.SchattkeS.SpethmannS.SanadW.SchroeckhS.SchimkeI.et al. (2015). Cardiac and renal function in a large cohort of amateur marathon runners. Cardiovasc. Ultrasound. 13:13. 10.1186/s12947-015-0007-6

  • 24

    HubbleK. M.FatovichD. M.GraskoJ. M.VasikaranS. D. (2009). Cardiac troponin increases among marathon runners in the Perth Marathon: the Troponin in Marathons (TRIM) study. Med. J. Aust.. 190, 9193.

  • 25

    JarvinenT. A.JarvinenM.KalimoH. (2013). Regeneration of injured skeletal muscle after the injury. Muscles Ligaments Tendons J. 3, 337345.

  • 26

    JeeH.JinY. (2012). Effects of prolonged endurance exercise on vascular endothelial and inflammation markers. J. Sports Sci. Med. 11, 719726.

  • 27

    JeeH.ParkJ.OhJ.-G.LeeY.-H.ShinK.-A.KimY.-J. (2013). Effect of a prolonged endurance marathon on vascular endothelial and inflammation markers in runners with exercise-induced hypertension. Am. J. Pbys. Med. Rehabil. 92, 513522. 10.1097/PHM.0b013e31829232db

  • 28

    KarstoftK.SolomonT. P.LayeM. J.PedersenB. K. (2013). Daily marathon running for a week–the biochemical and body compositional effects of participation. J. Strength Cond. Res. 27, 29272933. 10.1519/JSC.0b013e318289e39d

  • 29

    KasprowiczK.ZiemannE.RatkowskiW.LaskowskiR.KaczorJ. J.DadciR.et al. (2013). Running a 100-km ultra-marathon induces an inflammatory response but does not raise the level of the plasma iron-regulatory protein hepcidin. J. Sports Med. Phys. Fitness. 53, 533537.

  • 30

    KimH. J.LeeY. H.KimC. K. (2007). Biomarkers of muscle and cartilage damage and inflammation during a 200 km run. Eur. J. Appl. Physiol. 99, 443447. 10.1007/s00421-006-0362-y

  • 31

    KimY. J.AhnJ. K.ShinK. A.KimC. H.LeeY. H.ParkK. M. (2015). Correlation of cardiac markers and biomarkers with blood pressure of middle-aged marathon runners. J. Clin. Hypertens.17, 868873. 10.1111/jch.12591

  • 32

    KłapcinskaB.WaskiewiczZ.ChrapustaS. J.Sadowska-KrepaE.CzubaM.LangfortJ. (2013). Metabolic responses to a 48-h ultra-marathon run in middle-aged male amateur runners. Eur. J. Appl. Physiol.113, 27812793. 10.1007/s00421-013-2714-8

  • 33

    KrzeminskiK.BuraczewskaM.MiśkiewiczZ.DabrowskiJ.SteczkowskaM.KozaczA.et al. (2016). Effect of ultra-endurance exercise on left ventricular performance and plasma cytokines in healthy trained men. Biol. Sport. 33, 6369. 10.5604/20831862.1189767

  • 34

    LiberatiA.AltmanD. G.TetzlaffJ.MulrowC.GøtzscheP. C.IoannidisJ. P.et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br. Med. J. 339:b2700. 10.1136/bmj.b2700

  • 35

    MartinD. E.CoeP. N. (2007). Entrenamiento para Corredores de Fondo y Medio Fondo. Paidotribo.

  • 36

    MattuschF.DufauxB.HeineO.MertensI.RostR. (2000). Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int. J. Sports Med.21, 2124. 10.1055/s-2000-8852

  • 37

    MeeusenR.DuclosM.FosterC.FryA.GleesonM.NiemanD.et al. (2013). Prevention, diagnosis, and treatment of the overtraining syndrome: joint consensus statement of the European College of Sport Science and the American College of Sports Medicine. Med. Sci. Sports Exerc. 45, 186205. 10.1249/MSS.0b013e318279a10a

  • 38

    MeSH (2015). MeSH (Medical Subject Headings) is the NLM Controlled Vocabulary Thesaurus Used for Indexing Articles for PubMed. Available online at: http://www.ncbi.nlm.nih.gov/mesh/ (Acessed November 1, 2015).

  • 39

    MilletG. Y.TomazinK.VergesS.VincentC.BonnefoyR.BoissonR. C.et al. (2011). Neuromuscular consequences of an extreme mountain ultra-marathon. PLoS ONE6:e17059. 10.1371/journal.pone.0017059

  • 40

    MohamedS.LamyaN.HamdaM. (2016). Effect of maximal versus supra-maximal exhausting race on lipid peroxidation, antioxidant activity and muscle-damage biomarkers in long-distance and middle-distance runners. Asian J. Sports Med. 7:e27902. 10.5812/asjsm.27902

  • 41

    MohlenkampS.BoseD.MahabadiA. A.HeuschG.ErbelR. (2007). On the paradox of exercise: coronary atherosclerosis in an apparently healthy marathon runner. Nat. Clin. Pract. Cardiovasc. Med. 4, 396401. 10.1038/ncpcardio0926

  • 42

    MoldoveanuA. I.ShephardR. J.ShekP. N. (2000). Exercise elevates plasma levels but not gene expression of IL-1beta, IL-6, and TNF-alpha in blood mononuclear cells. J. Appl. Physiol.4, 14991504.

  • 43

    MoldoveanuA. I.ShephardR. J.ShekP. N. (2001). The cytokine response to physical activity and training. Sports Med. 31, 115144. 10.2165/00007256-200131020-00004

  • 44

    Mrakic-SpostaS.GussoniM.MorettiS.PrataliL.GiardiniG.TacchiniP.et al. (2015). Effects of mountain ultra-marathon running on ros production and oxidative damage by micro-invasive analytic techniques. PLoS ONE10:e0141780. 10.1371/journal.pone.0141780

  • 45

    NeidhartM.Müller-LadnerU.FreyW.BosserhoffA. K.ColombaniP. C.Frey-RindovaP.et al. (2000). Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthr. Cartil.8, 222229. 10.1053/joca.1999.0293

  • 46

    NgQ. Y.LeeK. W.ByrneC.HoT. F.LimC. L. (2008). Plasma endotoxin and immune responses during a 21-km road race under a warm and humid environment. Ann. Acad. Med. Singap.37, 307314.

  • 47

    NickelT.EmslanderI.SisicZ.DavidR.SchmadererC.MarxN.et al. (2012). Modulation of dendritic cells and toll-like receptors by marathon running. Eur. J. Appl. Physiol.112, 16991708. 10.1007/s00421-011-2140-8

  • 48

    NielsenH. G.ØktedalenO.OpstadP. K.LybergT. (2016). Plasma cytokine profiles in long-term strenuous exercise. J. Sports Med.2016:7186137. 10.1155/2016/7186137

  • 49

    NiemanD. C. (2009). Immune function responses to ultramarathon race competition. Med. Sport.13, 189196. 10.2478/v10036-009-0031-4

  • 50

    NiemanD. C.DumkeC. I.HensonD. A.McAnultyS. R.McAnultyL. S.LindR. H.et al. (2003). Immune and oxidative changes during and following the Western States Endurance Run. Int. J. Sports Med. 24, 541547. 10.1055/s-2003-42018

  • 51

    NiemanD. C.DumkeC. L.HensonD. A.McAnultyS. R.GrossS. J.LindR. H. (2005). Muscle damage is linked to cytokine changes following a 160-km race. Brain Behav. Immun. 19, 398403. 10.1016/j.bbi.2005.03.008

  • 52

    NiemanD. C.JohanssenL. M.LeeJ. W. (1989). Infectious episodes in runners before and after a roadrace. J. Sports Med. Phys. Fitness29, 289296.

  • 53

    NiemanD. C.JohanssenL. M.LeeJ. W.ArabatzisK. (1990). Infectious episodes in runners before and after the Los Angeles Marathon. J. Sports Med. Phys. Fitness30, 316328.

  • 54

    NiemanD. C.MeaneyM. P.JohnC. S.KnaggeK. J.ChenH. (2016). 9- and 13-Hydroxy-octadecadienoic acids (9+13 HODE) are inversely related to granulocyte colony stimulating factor and IL-6 in runners after 2 h running. Brain Behav. Immun. 56, 246252. 10.1016/j.bbi.2016.03.020

  • 55

    NiessA. M.SommerM.SchlotzE.NorthoffH.DickhuthH. H.FehrenbachE. (2000). Expression of the inducible nitric oxide synthase (iNOS) in human leukocytes: responses to running exercise. Med. Sci. Sports Exerc.32, 2201225. 10.1097/00005768-200007000-00006

  • 56

    O'BrienM. (2012). The reciprocal relationship between inflammation and coagulation. Top. Companion Anim. Med. 27, 4652. 10.1053/j.tcam.2012.06.003

  • 57

    O'KeefeJ. H.LavieC. J. (2013). Run for your life…at a comfortable speed and not too far. Heart99, 516519. 10.1136/heartjnl-2012-302886

  • 58

    O'KeefeJ. H.VogelR.LavieC. J.CordainL. (2010). Achieving hunter-gatherer fitness in the 21(st) century: back to the future. Am. J. Med. 123, 10821086. 10.1016/j.amjmed.2010.04.026

  • 59

    PapassotiriouI.AlexiouV. G.TsironiM.SkenderiK.SpanosA.FalagasM. E. (2008). Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur. J. Clin. Invest. 38, 276279. 10.1111/j.1365-2362.2008.01935.x

  • 60

    PedersenB. K. (2011). Muscles and their myokines. J. Exp. Biol. 214, 337346. 10.1242/jeb.048074

  • 61

    PedersenB. K. (2013). Muscle as a secretory organ. Compr. Physiol.3, 13371362. 10.1002/cphy.c120033

  • 62

    PedersenB. K.FebbraioM. A. (2012). Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457465. 10.1038/nrendo.2012.49

  • 63

    PetersE. M.BatemanE. D. (1983). Ultramarathon running and upper respiratory tract infections. An epidemiological survey. S. Afr. Med. J. 64, 582584.

  • 64

    PetersE. M.RobsonP. J.KleinveldtN. C.NaickerV. L.JogessarV. D. (2004). Hematological recovery in male ultramarathon runners: the effect of variations in training load and running time. J. Sports Med. Phys. Fitness44, 315321.

  • 65

    PetersenA. M.PedersenB. K. (2005). The anti-inflammatory effect of exercise. J. Appl. Physiol.98, 1541162. 10.1152/japplphysiol.00164.2004

  • 66

    RehmK. E.ElciO. U.HahnK.MarshallG. D.Jr. (2013). The impact of self-reported psychological stress levels on changes to peripheral blood immune biomarkers in recreational marathon runners during training and recovery. Neuroimmunomodulation20, 64176. 10.1159/000346795

  • 67

    ReihmaneD.JurkaA.TretjakovsP.DelaF. (2013). Increase in IL-6, TNF-alpha, and MMP-9, but not sICAM-1, concentrations depends on exercise duration. Eur. J. Appl. Physiol. 113, 851858. 10.1007/s00421-012-2491-9

  • 68

    RidkerP. M.RifaiN.RoseL.BuringJ. E.CookN. R. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 15571565. 10.1056/NEJMoa021993

  • 69

    SampsonM.McGowanJ.CogoE.GrimshawJ.MoherD.LefebvreC. (2009). An evidence-based practice guideline for the peer review of electronic search strategies. J. Clin. Epidemiol. 62, 944952. 10.1016/j.jclinepi.2008.10.012

  • 70

    SampsonM.McGowanJ.TetzlaffJ.CogoE.MoherD. (2008). No consensus exists on search reporting methods for systematic reviews. J. Clin. Epidemiol.61, 748754. 10.1016/j.jclinepi.2007.10.009

  • 71

    SantosR. V.TufikS.De MelloM. T. (2007). Exercise, sleep and cytokines: is there a relation?Sleep Med. Rev.11, 231239. 10.1016/j.smrv.2007.03.003

  • 72

    SantosV. C.Levada-PiresA. C.AlvesS. R.Pithon-CuriT. C.CuriR.Cury-BoaventuraM. F. (2013). Changes in lymphocyte and neutrophil function induced by a marathon race. Cell Biochem. Funct.31, 237243. 10.1002/cbf.2877

  • 73

    SaraviaS. G.KnebelF.SchroeckhS.ZiebigR.LunA.WeimannA.et al. (2010). Cardiac troponin T release and inflammation demonstrated in marathon runners. Clin. Lab.56, 5158.

  • 74

    SaugyJ.PlaceN.MilletG. Y.DegacheF.SchenaF.MilletG. P. (2013). Alterations of neuromuscular function after the world's most challenging mountain ultra-marathon. PLoS ONE8:e65596. 10.1371/journal.pone.0065596

  • 75

    SchobersbergerW.Hobisch-HagenP.FriesD.WiedermannF.Rieder-ScharingerJ.VilligerB.et al. (2000). Increase in immune activation, vascular endothelial growth factor and erythropoietin after an ultramarathon run at moderate altitude. Immunobiology201, 611620. 10.1016/S0171-2985(00)80078-9

  • 76

    ScottJ. P.SaleC.GreevesJ. P.CaseyA.DuttonJ.FraserW. D. (2011). Effect of exercise intensity on the cytokine response to an acute bout of running. Med. Sci. Sports Exerc.43, 22972306. 10.1249/MSS.0b013e31822113a9

  • 77

    ShinY. O.LeeJ. B. (2013). Leukocyte chemotactic cytokine and leukocyte subset responses during ultra-marathon running. Cytokine61, 364369. 10.1016/j.cyto.2012.11.019

  • 78

    SiegelA. J.VerbalisJ. G.ClementS.MendelsonJ. H.MelloN. K.AdnerM.et al. (2007). Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am. J. Med. 120, 461.e11461.e17. 10.1016/j.amjmed.2006.10.027

  • 79

    SmithL. L. (2004). Tissue trauma: the underlying cause of overtraining syndrome?J. Strength Cond. Res. 18, 185193. 10.1519/00124278-200402000-00028

  • 80

    SteinackerJ. M.LormesW.ReissneckerS.LiuY. (2004). New aspects of the hormone and cytokine response to training. Eur. J. Appl. Physiol.91, 382391. 10.1007/s00421-003-0960-x

  • 81

    StirlingA. E.KerrG. A. (2006). Perfectionism and mood states among recreational and elite athletes. J. Sport Psychol. 8, 1327.

  • 82

    StuempfleK. J.ValentinoT.Hew-ButlerT.HechtF. M.HoffmanM. D. (2016). Nausea is associated with endotoxemia during a 161-km ultramarathon. J. Sports Sci.34, 16621668. 10.1080/02640414.2015.1130238

  • 83

    SuzukiK.NakajiS.YamadaM.LiuQ.KurakakeS.OkamuraN.et al. (2003). Impact of a competitive marathon race on systemic cytokine and neutrophil responses. Med. Sci. Sports Exerc. 35, 348355. 10.1249/01.MSS.0000048861.57899.04

  • 84

    SuzukiK.YamadaM.KurakakeS.OkamuraN.YamayaK.LiuQ.et al. (2000). Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. Eur. J. Appl. Physiol. 81, 281287. 10.1007/s004210050044

  • 85

    TaylorB. A.ZaleskiA. L.CapizziJ. A.BallardK. D.TroyanosC.BaggishA. L.et al. (2014). Influence of chronic exercise on carotid atherosclerosis in marathon runners. Br. Med. J. Open4:e004498. 10.1136/bmjopen-2013-004498

  • 86

    TomaszewskiM.CharcharF. J.PrzybycinM.CrawfordL.WallaceA. M.GosekK.et al. (2003). Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go?Arterioscler. Thromb. Vasc. Biol. 23, 16401644. 10.1161/01.ATV.0000087036.75849.0B

  • 87

    UchakinP. N.GotovtsevaE. P.Stray-GundersenJ. (2003). Immune and neurodocrine alterations in marathon runners. J. Appl. Res. 3, 483494.

  • 88

    VaisbergM.BachiA. L.LatrilhaC.DioguardiG. S.BydlowskiS. P.MaranhaoR. C. (2012). Lipid transfer to HDL is higher in marathon runners than in sedentary subjects, but is acutely inhibited during the run. Lipids47, 679686. 10.1007/s11745-012-3685-y

  • 89

    VaisbergM.SuguriV. M.GregorioL. C.LopesJ. D.BachiA. L. (2013). Cytokine kinetics in nasal mucosa and sera: new insights in understanding upper-airway disease of marathon runners. Exerc. Immunol. Rev. 19, 4959.

  • 90

    VernilloG.GiandoliniM.EdwardsW. B.MorinJ. B.SamozinoP.HorvaisN.et al. (2017). Biomechanics and physiology of uphill and downhill running. Sports Med.47, 615629. 10.1007/s40279-016-0605-y

  • 91

    VidebaekS.BuenoA. M.NielsenR. O.RasmussenS. (2015). Incidence of running-related injuries per 1000 h of running in different types of runners: a systematic review and meta-analysis. Sports Med. 45, 10171026. 10.1007/s40279-015-0333-8

  • 92

    WalshN. P.GleesonM.ShephardR. J.WoodsJ. A.BishopN. C.FleshnerM.et al. (2011). Position statement. Part one: immune function and exercise. Exerc. Immunol. Rev. 17, 663.

  • 93

    WaśkiewiczZ.KłapcinskaB.Sadowska-KrepaE.CzubaM.KempaK.KimsaE.et al. (2012). Acute metabolic responses to a 24-h ultra-marathon race in male amateur runners. Eur. J. Appl. Physiol.112, 16791688. 10.1007/s00421-011-2135-5

  • 94

    WilhelmM.ZuegerT.De MarchiS.RimoldiS. F.BruggerN.SteinerR.et al. (2014). Inflammation and atrial remodeling after a mountain marathon. Scand. J. Med. Sci. Sports24, 519525. 10.1111/sms.12030

  • 95

    ZaldivarF.Wang-RodriguezJ.NemetD.SchwindtC.GalassettiP.MillsP. J.et al. (2006). Constitutive pro- and anti-inflammatory cytokine and growth factor response to exercise in leukocytes. J. Appl. Physiol.100, 11241133. 10.1152/japplphysiol.00562.2005

Summary

Keywords

running, inflammation, marathon, half-marathon, athletes, immunology

Citation

Barros ES, Nascimento DC, Prestes J, Nóbrega OT, Córdova C, Sousa F and Boullosa DA (2017) Acute and Chronic Effects of Endurance Running on Inflammatory Markers: A Systematic Review. Front. Physiol. 8:779. doi: 10.3389/fphys.2017.00779

Received

19 July 2017

Accepted

22 September 2017

Published

17 October 2017

Volume

8 - 2017

Edited by

Kenneth Dormer, Liberty University, United States

Reviewed by

Beat Knechtle, Institute of Primary Care, University of Zurich, Switzerland; Leonardo Alexandre Peyré-Tartaruga, Federal University of Rio Grande do Sul (UFRGS), Brazil

Updates

Copyright

*Correspondence: Daniel A. Boullosa

This article was submitted to Exercise Physiology, a section of the journal Frontiers in Physiology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics